FDA Oncology Center of Excellence Crowdsourcing Initiative: Outreach to the Scientific Community to Identify Research Questions for Pooled Analyses of Oncology Clinical Trial Data.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 08 2023
Historique:
received: 24 10 2022
revised: 01 02 2023
accepted: 23 03 2023
pmc-release: 15 02 2024
medline: 16 8 2023
pubmed: 4 4 2023
entrez: 3 4 2023
Statut: ppublish

Résumé

The FDA Oncology Center of Excellence recently launched a crowdsourcing pilot to request ideas from the scientific community for research questions that FDA could address with pooled analyses of clinical trial data submitted to the agency for regulatory purposes. This effort builds on FDA's track record of publishing pooled analyses to explore scientific questions that cannot be addressed in a single trial due to limited sample size. The research crowdsourcing pilot tested a new approach for obtaining external input on regulatory science activities, because FDA is generally unable to share patient-level data outside of the agency due to federal disclosure laws and regulations protecting different types of data submitted in regulatory applications. We received 29 submissions over the 28-day crowdsourcing campaign, including one research idea that we are exploring for possible follow-up. Based on our experience with this pilot, we learned that crowdsourcing is a promising new approach to gather external input and feedback. We identified opportunities to build understanding in the external oncology community about the types of data typically included in regulatory applications and expand the dissemination of published FDA pooled analyses to help inform future drug development and clinical practice.

Identifiants

pubmed: 37011149
pii: 725050
doi: 10.1158/1078-0432.CCR-22-3240
pmc: PMC10523843
mid: NIHMS1885687
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2964-2972

Subventions

Organisme : Intramural FDA HHS
ID : FD999999
Pays : United States

Informations de copyright

©2023 American Association for Cancer Research.

Références

N Engl J Med. 2017 Mar 23;376(12):1178-1181
pubmed: 28328337
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Med. 2017 Nov;6(11):2595-2605
pubmed: 28960834
Lancet Oncol. 2020 Feb;21(2):250-260
pubmed: 31859246
Eur J Cancer. 2009 Jan;45(2):248-60
pubmed: 19095437
Eur J Cancer. 2021 Nov;157:140-152
pubmed: 34508996
Ann Oncol. 2020 Dec;31(12):1704-1708
pubmed: 32866625
JAMA Oncol. 2019 Oct 01;5(10):1481-1485
pubmed: 31343662
Blood Adv. 2018 Jan 23;2(2):116-119
pubmed: 29365319
J Clin Oncol. 2019 Oct 20;37(30):2730-2737
pubmed: 31116675
J Clin Oncol. 2019 Dec 20;37(36):3475-3483
pubmed: 31560580
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Ann Oncol. 2019 May 1;30(5):830-838
pubmed: 30796424
Lancet Oncol. 2018 Feb;19(2):229-239
pubmed: 29361469
J Clin Oncol. 2005 Dec 1;23(34):8664-70
pubmed: 16260700
Int J Epidemiol. 1999 Feb;28(1):1-9
pubmed: 10195657
Trends Cancer. 2021 May;7(5):395-399
pubmed: 33431338
PLoS One. 2011;6(6):e21101
pubmed: 21738610
Clin Cancer Res. 2021 Oct 1;27(19):5161-5167
pubmed: 33910935
N Engl J Med. 2016 Jan 21;374(3):276-7
pubmed: 26789876
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32107275
Stat Methods Med Res. 2008 Oct;17(5):467-75
pubmed: 18285439
Trials. 2019 Aug 19;20(1):513
pubmed: 31426840

Auteurs

Julie A Schneider (JA)

Oncology Center of Excellence, FDA, Silver Spring, Maryland.

Julia Eckstein (J)

Foundation Medicine, Cambridge, Massachusetts.

Kirsten B Goldberg (KB)

Oncology Center of Excellence, FDA, Silver Spring, Maryland.

Mark C Ascione (MC)

Office of Strategic Programs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland.

Thamar Bailey (T)

Office of Strategic Programs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland.

Kimberly Taylor (K)

Office of Strategic Programs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland.

Aisha M Coffey (AM)

Office of Communications, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland.

Darshini Satchi (D)

Division of Information Disclosure Policy, Office of Regulatory Policy, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland.

Howard Philips (H)

Division of Information Disclosure Policy, Office of Regulatory Policy, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland.

Rajeshwari Sridhara (R)

Oncology Center of Excellence, FDA, Silver Spring, Maryland.

Abhilasha Nair (A)

Office of Oncologic Diseases, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland.

Richard Pazdur (R)

Oncology Center of Excellence, FDA, Silver Spring, Maryland.
Office of Oncologic Diseases, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland.

Marc R Theoret (MR)

Oncology Center of Excellence, FDA, Silver Spring, Maryland.
Office of Oncologic Diseases, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH